1   **Highly efficient DNA-free gene disruption in the agricultural pest *Ceratitis capitata***

2   **by CRISPR-Cas9 RNPs**

3

4

5   Angela Meccariello[1], Simona Maria Monti[2], Alessandra Romanelli[3], Rita Colonna[1],

6   Pasquale Primo[1], Maria Grazia Inghilterra[1], Giuseppe Del Corsano[1], Antonio Ramaglia[4],

7   Giovanni Iazzetti[1], Antonia Chiarore[5], Francesco Patti[5], Svenia D. Heinze[6], Marco

8   Salvemini[1], Helen Lindsay[6,7], Elena Chiavacci[6], Alexa Burger[6], Mark D. Robinson[6,7],

9   Christian Mosimann[6], Daniel Bopp[6] and Giuseppe Saccone[1]

10

11   [1]Department of Biology, University of Naples "Federico II", 80126, Napoli, Italy

12   [2]Institute of Biostructure and Bioimaging (IBB-CNR), 80134, Naples, Italy

13   [3]Department of Pharmacy, University of Naples "Federico II", 80134, Napoli, Italy

14   [4]Department of Physics "E. Pancini", University of Naples "Federico II", 80126, Napoli,

15   Italy

16   [5]Stazione Zoologica Anton Dohrn, Center Villa Dohrn for Benthic Ecology, Punta San

17   Pietro, 80077, Ischia, Italy.

18   [6]Institute of Molecular Life Sciences, University of Zürich, Zürich 8057, Switzerland

19   [7]SIB Swiss Institute of Bioinformatics, University of Zürich, Zürich 8057, Switzerland

20

21

22

23   Author for correspondence: Giuseppe Saccone,

24   Department of Biology,

25   University of Naples "Federico II"

26   Complesso Universitario Monte Sant'Angelo

27   Building 7, room 0F-01

28   Via Cinthia, n. 26, 80126,

29   Napoli, Italy,

30   Tel: +39 081 2535009

31   Fax: +39 081 679233

32   e-mail: giuseppe.saccone@unina.it

33   +

34

35

36   Running head: efficient Cas9 gene disruption in the medfly

37   Key words: Cas9, *white eye*, *paired*, *Ceratitis capitata*, *Tephritidae*, *agricultural pest*,

38   *genetics, gene editing,*

39

40 **ABSTRACT**

41

42 The Mediterranean fruitfly *Ceratitis capitata* (medfly) is an invasive agricultural pest of

43 high economical impact and has become an emerging model for developing new genetic

44 control strategies as alternative to insecticides. Here, we report the successful adaptation

45 of CRISPR-Cas9-based gene disruption in the medfly by injecting *in vitro* pre-assembled,

46 solubilized Cas9 ribonucleoprotein complexes (RNPs) loaded with gene-specific sgRNAs

47 into early embryos. When targeting the eye pigmentation gene *white eye* (*we*)*, we

48 observed a high rate of somatic mosaicism in surviving G0 adults. Germline transmission

49 of mutated *we* alleles by G0 animals was on average above 70%, with individual cases

50 achieving a transmission rate of nearly 100%. We further recovered large deletions in the

51 *we* gene when two sites were simultaneously targeted by two sgRNAs. CRISPR-Cas9

52 targeting of the *Ceratitis* ortholog of the *Drosophila* segmentation *paired* gene (*Ccprd*)

53 caused segmental malformations in late embryos and in hatched larvae. Mutant

54 phenotypes correlate with repair by non-homologous end joining (NHEJ) lesions in the

55 two targeted genes. This simple and highly effective Cas9 RNP-based gene editing to

56 introduce mutations in *Ceratitis capitata* will significantly advance the design and

57 development of new effective strategies for pest control management.

58

59

60

61

62

63

64 **Introduction**

65

66   The Mediterranean fruitfly *Ceratitis capitata* (medfly) is an economically relevant

67 agricultural pest infesting more than 260 crop species, including fruits, vegetables, and

68 nuts[1]. Wild populations can be contained by the Sterile Insect Technique (SIT), an

69 eradication strategy based on the repeated release of large numbers of factory-grown

70 sterile males into infested areas[2,3]. *C. capitata* was the first non-Drosophilidae insect

71 species in which transposon-mediated germline transformation was established[4,5].

72 Various *Ceratitis* transgenic strains have been developed, aiming to improve SIT and

73 other pest control strategies[8-16]. Also embryonic RNA interference was successfully

74 applied to study *in vivo* functions of key *Ceratitis* genes controlling sex determination[6,7].

75 Nonetheless, a more comprehensive study of gene functions in *Ceratitis* will be needed to

76 further improve existing control strategies. To generate long-lasting and hereditable

77 changes in gene function, the CRISPR-Cas9 system with its modular and simple

78 components provides a promising tool to implement scalable, reproducible pest control

79 strategies[17,18]. Furthermore, transgene-based CRISPR-Cas9 can be used to produce

80 homozygous loss-of-function mutations as well as a novel gene drive system for insect

81 population control[19,21].

82   Various studies have reported the successful use of the Cas9 system to introduce

83 genome modifications in *Drosophila melanogaster* based on injecting different

84 combinations CRISPR-Cas9 reagents into embryos, such as DNA plasmids expressing

85 Cas9 protein plus single-guide RNA (sgRNA)[22], *in vitro*-transcribed *Cas9* mRNA plus

86 sgRNA[22,23], and sgRNA into transgenic flies that express Cas9 in the germ line[25,26]. Lee *et*

87 *al*., 2014 injected purified Cas9 protein preloaded with 2 RNAs, trRNA (transactivating

88 RNA) and gene-specific crRNA (CRISPR RNA), into *Drosophila* embryos and observed

89 a high rate of Cas9-induced lesions[27]. As Jinek *et al.,* 2012*,* and Basu *et al*., 2015 reported

90 that the use of a single sgRNA molecule, combining both trRNA and crRNA, is more

91 effective than the trRNA/ crRNA dual system[28], we opted for this technical

92 improvement[29].

93   Altogether, we decided on the strategy of injecting Cas9 ribonucleoprotein (RNP)

94 complexes into insect embryos for the following reasons: 1) preloaded Cas9 RNPs should

95 act immediately following injection; 2) RNPs potentially result in higher efficiencies

96 compared to other approaches; 3) there are potentially less off-target events[30,31]; and, 4)

97 Cas9 protein is more stable and robust than Cas9 mRNA, and can be generated with basic

98 protein purification strategies [30].

99   Here, we show that injecting *in vitro* generated Cas9-sgRNA RNPs into *C. capitata*

100 embryos is highly effective at inducing mono- and bi-allelic lesions of the targeted genes

101 in both somatic and germline cells.

102

103 **RESULTS**

104

105 **Cas9-induced somatic disruption of the *we* gene**

106 To test the feasibility of Cas9-mediated gene disruption in *Ceratitis*, we targeted the *white*

107 *eye* (*we*) gene, a locus required for eye pigmentation[4,5,32]. The *Ceratitis we* gene is the

108 ortholog of the X-linked *white* (*w*) gene in *Drosophila*[5] and is located on the *Ceratitis*

109 fifth chromosome[33,34]. The *we* gene is an ideal target to test Cas9-mediated disruption for

110 the following reasons: 1) lack of eye pigmentation is an easily scored phenotype; 2) a *we*-

111 mutant *Ceratitis* strain is available to test new loss-of-function alleles for

112 complementation, and 3) *we* function is cell-autonomous and hence somatic mutant cells

113 can be readily detected in the adult eye.

114 We used CHOPCHOP[35] to identify potential Cas9 target sequences in *we* and to design

115 three independent sgRNAs, *we*-g1, *we*-g2, and *we*-g3 **(Fig. 1A)**. Injections with unloaded

116 recombinant Cas9 protein caused an almost twofold lower survival rate (15-19%)

117 compared to buffer alone injections (30%), suggesting a measurable level of toxicity of

118   Cas9 protein in *Ceratitis* embryos **(Tab. 1)**. A slightly more pronounced toxicity of Cas9

119   was observed during transition from larvae to pupae (0.37.-0.49 compared to 0.84).

120   We next loaded recombinant Cas9 protein with individual sgRNAs *in vitro* and injected

121   the RNP complexes into early syncytial embryos of the wildtype Benakeion strain. We

122   aimed at targeting syncytial nuclei to maximize the efficiency of inducing NHEJ lesions.

123   A biallelic hit at this early stage is expected to produce large clones of mutant tissue in

124   injected individuals[22,30]. In this first round, we injected *we*-g1 RNPs in a buffer containing

125   300 KCl mM to improve solubilization of Cas9, as previously established to achieve

126   maximal Cas9 activity in zebrafish[30,36]. Of 240 injected embryos, 64 larvae hatched and 6

127   survived to adulthood **(Tab. 2)**. Three displayed a mosaic pattern of *white* unpigmented

128   ommatidia surrounded by wild-type pigmented ommatidia **(Fig. 1B**, **C** and **D)**. One of the

129   two eyes in one individual was completely white, suggesting that a biallelic gene

130   disruption event occurred at an early stage in the primordial lineage **(Fig. 1C)**. The

131   presence of mutations was confirmed by sequencing of PCR products spanning the

132   cleavage sites. Direct sequencing of amplified genomic DNA showed heterogeneity in

133   nucleotide calls around the cleavage site close to the protospacer-adjacent motif (PAM)

134   site, consistent with a range of different NJEH-induced alterations. Genomic *we* PCR

135   products were obtained from pools of injected larvae or single adult G0 flies. Indels,

136   mostly deletions, of variable length (Fig. 1E; *we*-g1, 14-21 bp), were detected in cloned

137   fragments, consistent with previous studies[18].

138   We performed additional rounds of embryos injections with *we*-g2 (150 mM KCl), and

139   *we*-g3 (300 mM KCl), and we subsequently observed either a lower percentage of adults

140   with eye pigmentation mosaicism (4% for *we*-g2) or none (we-g3). Injections of *we*-

141   g1/*we*-g2 RNPs (150 mM KCl) led to 23% adult mosaics **(Tab. 2)**, but this duplex RNP

142   targeting did not produce any deletions between the two targeted sites; furthermore, only

143   *we*-g2 induced indels were observed (reported in **Fig. 1E**, *we*-g2: 4-6). Again, sequencing

144   of cloned PCR products revealed NHEJ deletions, ranging from 2-21 bp, relative to the

145   PAM site of *we*-g2. 3 additional series injections of *we*-g1+ *we*-g2 into a total of 600

146   embryos (data not shown), also at 300 mM KCl, confirmed the lack of deletion between

147   the two targeted sites by PCR analysis on genomic DNA. The absence of a deletion

148   spanning the two targeted sites less than 100 bp apart can be explained, for example, by

149   steric hindrance which prevents that two adjacent Cas9-sgRNA complexes can cut both

150   sites simultaneously. Indeed, when injecting simultaneously *we*-g2 and *we*-g3 RNPs (in

151   300 mM KCl) in early embryos, we did recover deletions spanning the 2 more distant

152   targeted sites, ranging from 304 bp to 651 bp **(Fig. 1F)**.

153

154

155   **Cas9-induced germ line disruption of the *we* gene**

156

157   To test for germline transmission of Cas9-induced *we* alleles, 9 injected G0 red eyed flies

158   (3 *we*-g1/RNP flies and 6 *we*-g2 RNP flies; **Tab. 3**) were individually crossed with *we*-

159   mutant partners (carrying a *w1* allele having a frameshift mutation in the sixth exon[32];

160   Genbank AH010565.2). Seven injected flies sired G1 progeny, six of which gave rise to

161   mutant *white eye* flies **(Fig. 2A)**, with a highly variable transmission rate (1.5% - 100%**;**

162   **Tab. 3)**. Non-complementation of the CRISPR-Cas9-induced mutations confirms that

163   they are allelic to the original *we* mutation **(Fig. 2A)**. Of the three *we*-g1 injected

164   individuals, two males sired small batches of progeny in which 100% (*we*-g1#1; 6 flies)

165   and 45% (*we*-g1#2*; 10 out of 22*), respectively, displayed the mutant phenotype **(Tab. 3).**

166   Of the six *we*-g2 injected individuals, 4 males produced various proportions of G1 mutant

167   white-eyed progeny. Remarkably, the *we*-g1#1 and *we*-g2#5 lines gave rise to 100% and

168   98% G1 white-eyed offspring, respectively **(Tab. 3)**. Thus, our results demonstrate that

169   Cas9 activity is highly effective in the germ line, producing mostly mutant primordial

170   germ cells.

171   We randomly chose 4 out of 16 G1 *we*-g1-targeted mutant flies (two from *we*-g1#1 cross

172   and two from *we*-g1#2 cross) and 2 out of 166 *we*-g2-targeted mutant G1 flies (one from

173   *we*-g2#4 line and one from *we*-g2#5 line)**(Tab. 3)**. Sequencing of cloned PCR products

174   revealed that the 4 *we*-g1 G1 flies inherited one allele from the *we* parent and three

175   different *we*^{CRISPR} alleles from the injected G0 fathers. We found an identical *we* deletion

176   of 14 bp (labeled "-3:14D" in **Fig. 1E** and **Fig. 2B**) in both analyzed flies from the *we*-

177   g1#2 cross*,* suggesting that they inherited the same mutation from their common male

178   founder **(Fig. 2B: we-*g1*)**. Mutant G1 flies of the *we*-g1#2 line carried two different

179   alleles (4 bp and 10 bp deletions; -4:4D and -5:10D, respectively)**.** All three Cas9-induced

180   alleles are small deletions, causing frame-shifts in exon 2 of the *we* coding region, and

181   failed to complement the original *we* mutation. Two *we*-g2 targeted G1 mutant flies

182   carried two novel alleles, one with a 4 bp deletion (we-g2#4 line; Table 3) and one with a

183   long 84 bp deletion (we-g2#5 line; Table 3) (**Fig. 2B**: we-*g2*; 84bp deletion not shown).

184   To study genes for which no mutant alleles are available, it would be useful to screen for

185   mutant phenotypes by *inter se* crossings of G0 individuals in which the germ line has

186   been targeted by CRISPR-Cas9. To test this possibility, we injected *we*-g3 or *we*-g2+g3

187   RNPs (Tab. 3; 4th and 5th rows). All of the surviving G0 flies, 20 and 38 respectively, did

188   not show somatic mosaicism in the eyes **(Tab. 3)**. When crossed *inter se* **(Tab. 4),** we

189   recovered two mutant individuals out of 26 G1 flies (8%) from the *we*-g3 cross and three

190   out of 184 flies (2%) from the *we*-g2+*we*-g3 cross, demonstrating the feasibility of this

191   crossing strategy.

192   Sequencing of the targeted regions in 2 G1 flies of the *we-g3* cross identified, as

193   expected, 4 novel *we* alleles. 2 out of 3 tested G1 flies of the *we-g2+we-g3* cross all

194   exhibit identical 9bp deletion *we* allele at *we*-g3, most likely derived from the same G0

195   injected parent **(Fig. 2B: we-*g3*)**. One of these 3 flies carried a large deletion of 651 bp

196   resulting from duplex targeting with *we*-g2+*we*-g3 **(Fig. 2B: we-*g2*+*g3*)**.

197   Taken together, our analysis revealed that a cross of 20 and 38 adult G0 flies from Cas9

198   RNP-injected embryos can lead to 2-8% of mutant G1 flies bearing heteroallelic loss-of-

199   function combinations within two medfly generations (less than 2 months).

200

201   **Cas9-induced somatic disruption of the *Ceratitis paired* gene**

202   The zygotic activity of the *Drosophila paired* gene (*prd*) is required for proper

203   segmentation of the developing embryo[37]. *Drosophila* embryos homozygous for *prd* loss-

204   of-function alleles lack every other segment and die before hatching (pair-rule

205   phenotype)[37]. Early segmentation events are well conserved amongst higher dipterans[38];

206   we therefore hypothesized that the *prd* ortholog in *Ceratitis* (Genbank JAB89073.1), will

207   display comparable segmental defects and lethality when disrupted. We used

208   CHOPCHOP to select one target sequences in *Ccprd* (*Ccprd*-g1) in a region encoding the

209   conserved PRD domain (green box; **Fig. 3A**). Two injections series with *Ccprd-g1* (300

210   mM KCl), resulted in survival rates of hatching embryos of 35% and 24%, respectively

211   **(Tab. 5)**.–A slightly more pronounced lethality of *Ccprd*-g1 was observed (0.24-0.35)

212   compared with the *we*-g1 and *we*-g2 RNPs effects (0.43-0.44; Table 2). Comparing these

213   values to the 33% of survivors injected with buffer alone, RNP-mediated targeting of

214   *Ccprd* led to a 3-6 times higher mortality. Approximately 1-5% of the injected embryos

215   showed either delayed development (late hatching rate) or arrested at late stages of

216   embryogenesis, both effects we did not observe by injection of Cas9 alone (data not

217   shown). Some lethality was observed at larval stages, with few individuals showing

218   impaired locomotor activity and abnormal cuticular morphology. Only 5-11% of injected

219   individuals developed to adulthood, with a delay of 1-2 days compared to flies injected

220   with buffer alone or with *white* targeting RNPs **(Tab. 5)**.

221   Approximately 90% of the embryos that failed to hatch (respectively, 90 embryos

222   and 160 embryos; Tab. 5) displayed disorganized cuticular structures. Some were up to

223   50% shorter in size compared to control embryos and consisted of a reduced number of

224   segments **(Fig. 3 B)**. This phenotype is reminiscent of the *pair rule* phenotype described

225   for *Drosophila*[37,39].

226   The phenotypic variability is likely a result of mutagenesis-caused mosaicism, with a

227   variable proportion of wildtype cells (*Ccprd*[+]/*Ccprd*[+] or *Ccprd*[+]/*Ccprd*[-]) and mutant cells

228   (*Ccprd*[-]/*Ccprd*[-]) in these affected individuals. Because of the mosaic nature of Cas9-

229   induced lesions in the cell-autonomously acting *Ccprd*, a complete pair rule phenotype

230   was not expected. The observed phenotypes are consistent with the occurrence of large

231   mutant clones caused by biallelic targeting. Sequencing of individuals injected with

232   *Ccprd*-g1 unveiled lesions in the targeted regions of the *Ccprd* locus **(Fig. 3D)**. We

233   conclude that *Ccprd-g1* targeting was effective in inducing lesions in *Ccprd* and causing

234   segmental malformations.

235

236   **DISCUSSION**

237   Over the last two decades, novel genetic strategies in pest insect management have been

238   developed to improve their effectiveness in the field. Genetic technologies used thus far

239   in the medfly have been based on the random integration of transposable elements into

240   the genome[4], site-specific modification of the randomly integrated transgene[12] and

241   embryonic or transgene-mediated RNA interference (RNAi)[6,15]. The disadvantage is that

242   such genetically modified medfly must be continuously tested with respect to fitness and

243   competitiveness as well as to stability and expression of the transgene[40]. The CRISPR-

244   Cas9 technology offers the possibility to avoid random integration of exogenous DNA

245   but instead provides a more robust and controlled approach to introduce new genetic

246   features, which can be either addition of exogenous DNA or nucleotides changes in

247   specific genes. Here, we explored the use of Cas9-sgRNA RNP complexes, avoiding

248   plasmid-based or DNA-mediated delivery of Cas9. This DNA-free (plasmid or integrated

249   transgene) method may allow to circumvent existing regulatory restrictions which are in

250   effect in most nations concerning the use of GM organisms in the field. This "green"

251   editing technology may facilitate global acceptance not only for plants or fungi, but also

252   for insect pest control[41].

253   The use of preloaded Cas9-sgRNA complexes is becoming a successful approach for

254   targeted disruption of genes in a growing number of insect species, including *Drosophila*

255   *melanogaster*[27] and *Aedes aegypti*[29]. To our knowledge, this is the first report showing

256   that the same approach can be used to effectively mutate genes in a major agricultural

257   pest insect such as *Ceratitis capitata,* with up to 100% mutagenesis rate in the germ line.

258   As observed by Lee *et al.* (2014), Cas9-sgRNA complexes act immediately but are

259   rapidly degraded, often within few hours after administration[27]; similarly Kim *et al.*

260   (2014) reported that Cas9 protein is degraded within 24 h after being applied to cultured

261   human cell lines[17]. As the short-lived activity of Cas9 prevents the induction of late

262   mutational events, this may help to reduce off-target effects and mosaicism of mutant and

263   wild type tissues in the injected individuals.

264   We report here that Cas9-mediated NJEH events generates lesions in the *Ceratitis we* and

265   *Ccprd* genes. Targeting the *we* gene caused red-white eye mosaicism in up to 50% of

266   injected individuals, indicating a very high rate of somatic bi-allelic hits. Transmission of

267   *we* mutated alleles to G1 progeny was found to be highly effective being close to 100%.

268   Lee *et al.*, (2014)[27] observed a 5-time lower germline transmission rate (20%) when

269   targeting *Drosophila* genes using RNPs. One possible explanation is that the higher

270   concentration of KCl (300 mM) used in our study increases Cas9 stability and/or

271   solubility[30]. Injecting RNP complexes in *Aedes aegypti*, Basu *et al.*, (2015) found a

272   germline transmission rate of induced mutations up to 90%[28]; yet this rate was determined

273   with high-resolution melt analysis (HRMA) which detects also monoallelic somatic gene

274   editing. Instead in our study, the germline transmission rate was calculated scoring

275   recessive G1 phenotypes, which is an under-estimation compared with HRMA. Gilles *et*

276   *al.*, (2015) observed up to 80% of mutant G0 progeny by co-injecting Cas9 mRNA and

277   sgRNAs into the coleopteran *Tribolium castaneum* embryos[43]. Here, the authors scored a

278   phenotype (lack of fluorescence) targeting a single copy dominant marker transgene. As

279   we scored biallelic mutations of the endogenous *we* gene in G0 somatic mosaics, our

280   efficiency rate of somatic mutation is much higher.

281   Several studies have reported that the simultaneous use of 2 Cas9-sgRNAs is an effective

282   means to generate deletions of sequences between two targeted sites[29,44]. While *we*-g1 and

283   *we*-g2 RNPs were individually effective in gene editing, the absence of a deletion

284   spanning the two targeted sites less than 100 bp apart in 4 different series of experiments

285   (at 150 mM and 300 mM KCl) can be explained for example by steric hindrance which

286   prevents that two adjacent Cas9-sgRNA complexes can cut both sites simultaneously. In

287   contrast, RNPs targeting (at 300 mM KCl) two sites more distant of each other e.g. *we*-g2

288   and *we*-g3 (489 bp) simultaneously was effective in generating long deletions in both

289   somatic and germ-line cells. Hence it is conceivable that a multiplex CRISPR-Cas9

290   system can be used to remove for instance protein domains encoded by single exons in

291   the medfly.

292   To test the functionality of purified Cas9 protein we established a fast *in vivo* assay by

293   targeting the *Ceratitis* zygotic segmentation gene *Ccprd*. Indeed, this test allows to screen

294   for mutant phenotypes within 3 days and subsequent sequence analysis of the targeted

295   site can be performed to confirm the presence of lesions.

296   CRISPR-Cas9 will be helpful in investigating natural traits of this major agricultural pest,

297   for example invasiveness and host adaptation, reproduction, olfaction (fruit seeking

298   behavior), chemoreception, toxin and insecticide metabolism[45]. The recent availability of

299   a medfly genome draft combined with the successful implementation of CRISPR genome

300   editing technology, as reported here, opens the road to transfer basic knowledge to

301   applied research. Next challenges for the CRISPR-Cas9 technology in *Ceratitis* will be to

302   exploit homology-directed recombination for genome editing, either to insert transgenes

303   in specific regions or to replace DNA sequences with slightly mutated ones.

304

305

306   **Methods**

307

308   **Rearing of *Ceratitis capitata* and strains used.** The *C. capitata* strains were reared in

309   standard laboratory conditions at 25 °C, 70% relative humidity and 12h /12h light–dark

310   cycles. Adult flies were fed with a mixture of yeast and sucrose powder (1v/2v). Eggs

311   were collected in dishes filled with water and after hatching transferred to larval food (30

312   g, sugar 30 g, yeast extract 30 g, cholesterol stock 10 ml, HCl stock 2 ml, Benzoic stock

313   8,5 ml, water 400 ml). Pupae were collected and stored in dishes until eclosion.

314   Following strains were used in this study: a) the wildtype strain Benakeion which was

315   obtained from P. A. Mourikis (Benakeion Institute of Phytopathology, Athens, Greece)

316   and b) the mutant *we/we* strain Benakeion[4] kindly provided by Kostas Bourtzis (Pest

317   Control of FAO/IAEA, Seiberdorf, Austria).

318

319   **Cas9 protein purification**. We produced our own supply of Cas9 endonuclease by

320   expressing HIS tagged protein in bacteria[27] and following the purification protocol

321   described in Monti *et al.*[46] and Dathan *et al.*[47]. The *pET* plasmid which carries the

322   recombinant His-tagged Cas9 gene was transformed into BL21(DE3) bacterial strain.

323   Protein expression was induced in presence of 0.5 mM isopropyl-β-D-

324   thiogalactopyranoside (IPTG) for 16 h at 22 °C. 100 ml cell pellet was resuspended in 10

325   ml of cold lysis buffer (50 mM Phosphate, 500 mM NaCl, 10 mM Imidazole, 1 mM DTT,

326   pH 8) supplemented with protease inhibitor mixture (1 mM PMSF and 1.0 mg/ml of

327   lysozyme) and incubated at room temperature for 30 min. Cells were disrupted by

328   sonication on ice with 10 s on and 10 s off cycles for 10 min. After centrifugation at

329   14,000 rpm for 30 min at 4 °C, supernatant was loaded on an ÅKTA FPLC

330   chromatography column using a 1 ml HisTrap HP. The column was washed with lysis

331   buffer and bound protein was eluted using a gradient from 10 mM to 500 mM imidazole.

332   Protein elution was monitored by measuring absorbance at 280 nm and resulting fractions

333   were analyzed by 15% SDS-PAGE. The eluted fractions were dialyzed against buffer (20

334   mM HEPES, 150 mM KCl, 1 mM DTT, 10% glycerol, pH 7.5). Analysis of the protein

335   by gel-filtration was compared with calibration obtained with marker proteins run on the

336   column under the same conditions. Gel-filtration analyses were carried out on a Superdex

337   200 increase 10/300 GL column.

338

339   **sgRNA synthesis and RNP complex assembly** sgRNA were designed using

340   CHOPCHOP[35] https://chopchop.rc.fas.harvard.edu/. CHOPCHOP lists the Target

341   Sequence (including the PAM), the genomic location of the target, the strand (- or +), the

342   GC content of the guide and the Off-targets. Templates for sgRNA production were

343   designed as described by Bassett et al (2013)[23]. Following 3 templates for sgRNA

344   production were generated to target the *we* gene:

345   g1:

346   5'GAAATTAATACGACTCACTATA<u>GAGTAAGTGAGATTATCC</u>GGTTTTAGAGC

347   TAGAAATAGC3'

348   g2:

349   5'GAAATTAATACGACTCACTATA<u>GCTGGTGAATCGTGTGAAGG</u>GTTTTAGAG

350   CTAGAAATAGC3'

351   g3:

352   5'GAAATTAATACGACTCACTATA<u>CGGGTGAAGGGTTTATCGGG</u>GTTTTAGAG

353   CTAGAAATAGC3'

354   (respectively with PAMs CGG, GGG and TGG).

355   Common sgReverse (PAGE purified):

356   5'AAAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATGGACTAGCCTTATTTT

357   AACTTGCTATTTCTAGCTCTAAAACAAC-3'

358   Following 2 templates for sgRNA production were generated to target the *Ccprd* gene:

359   Prd-g1:

360   5'GAAATTAATACGACTCACTATA<u>GGTCGCGTCAATCAATTAGG</u>GTTTTAGAG

361   CTAGAAATAGC-3'

362   Prd-g2:

363   5'GAAATTAATACGACTCACTATA<u>AGAATCCCAGCATATTTTC</u>GGTTTTAGAGC

364   TAGAAATAGC3

365   (respectively with PAMs TGG and TGG).

366   Common sgReverse (PAGE purified):

367   5'AAAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATGGACTAGCCTTATTTT

368   AACTTGCTATTTCTAGCTCTAAAACAAC-3'

369   The PCR was performed using Q5® High-Fidelity DNA Polymerase (NEB). The DNA

370   template was cleaned by phenol/chloroform extractions and EtOH precipitation at -20°C.

371   Following 14,000 rpm 15 min 4°C, the pellet was resuspended in 40μl ddH2O.   For

372   synthesis of sgRNA we followed the instructions of Megatranscript T7 kit (Ambion)

373   using 400 ng of target template with 5' flanking T7 promoter as starting material. After

374   RNA synthesis, DNA template was removed by incubating with TurboDNase (Mmessage

375   mMACHINE T7 Ultra Kit, Ambion) for 15 min at 37 °C.

376   The reaction for complex formation was prepared by mixing 1.8 μg of purified Cas9

377   protein with approximately 1 μg of sgRNA in a 5 μl volume containing 150 or 300 mM

378   KCl, according to the protocols proposed by Lee et al. [27], and Burger et al.[30], respectively.

379   The freshly prepared mixture was incubated for 10 min at 37°C and kept on ice prior to

380   injections.

381

382   **Microinjection of sgRNA-Cas9 RNP complexes** Embryos of the wildtype Benakeion

383   strain were collected 1 hour after egg lay and chorion membrane was manually removed.

384   Dechorionated embryos were aligned and glued to 3MM doubleside tape on a cover slip

385   with posterior ends pointing to injection site and covered with Oil S700 (Sigma). A glass

386   needle was pulled with a Narishige PB-7 and manually broken to produce sharp edges at

387   the injection end. The needle was filled with 1 μl of preloaded sgRNA-Cas9 mix and

388   injected into the posterior end of embryos. A Leica inverted microscope DM-IRB was

389   used for micro-injections. After injection excess of oil was carefully removed and cover

390   slip were put on an agar plate overnight at 25°C. Surviving larvae were transferred after

391   24 hours to petri dishes containing medfly larval food. A Jove video is available,

392   describing a similar method of medfly embryos microinjection[50]

393

394   **Genomic analysis of Cas9-mediated lesions** DNA extraction was performed, with

395   minor modifications, according to the protocol of Holmes and Bonner [**1973**][48].

396   Individual larvae or adult flies were placed in a 1.5 ml Eppendorf tube and manually

397 crushed with a pestle in 200 μl Holmes Bonner buffer (urea 7 M, Tris-HCl 100 mM pH

398 8.0, EDTA 10 mM pH 8.0, NaCl 350 mM, SDS 2%). Subsequently, DNA was purified

399 by phenol/chloroform extraction, followed by chloroform extraction and ethanol

400 precipitation. The pellet was resuspended in 30 μl or 100 μl water containing RNaseA.

401 The resulting DNA was used as template to amplify the region encompassing the target

402 sites, using the following primers

403 F-*we*: 5'GCCCTACGAGCAATCCTCT 3'

404   R1-*we*: 5'TCTGCAATGAGCGTCATATAC 3'

405   R2-*we*: 5'TTCTGCGATAGCTTTTTCAACA 3'

406 F-*Ccprd* 5'CTTCGACACACAACCGTGTG 3'

407 R-*Ccprd* 5'AGAATGCTTGTGGGAATGTTCT 3'

408

409 DreamTaq (Life Technologies) polymerase was used for PCR amplifications according to

410 the manufacturer's instructions. The PCR products were purified with StrataPrep PCR

411 Purificaton Kit (Agilent Technologies) and subcloned using with StrataClone PCR

412 cloning Kit (Agilent Techologies). Positive clones were sequenced by Sanger method and

413 ABI 310 Automated Sequencer (Applied Biosystems). CrispRVariants and panel plots

414 were compiled from primary Sanger sequencing data as described in [30,49], as well as using

415 new functionality to display duplex guide pairs (e.g., **Fig. 1F**) as implemented in the

416 development version 1.3.6.

417

418

419

437

438 **Contributions:** AM and GS designed the experiments. AM and SMM expressed and

439 purified the CAS9, sgRNAs design and selection was performed by AM and MR, AM

440 produced sgRNAs, MR and HL analyzed indels and produced CrispRVariants plots. DB

441 hosted AM and GS at University of Zurich to establish CRISPR/CAS9 technology in the

442 medfly and in *Musca domestica*; the purified CAS9 was tested in zebrafish by CM who

443 together with AB provided protocols and technical advices to improve Cas9

444 stability/efficiency; GS wrote the manuscript with major inputs from DB and

445 contributions by AM, MR and CM. AM and GS supervised four master students, RC,

446 MGI, PP, GDC, who contributed to this study with medfly rearing, crossings, PCR

447   analysis, cloning and sequencing. EC, MS, FP and AC analyzed DNA clones from

448   injected individuals. AR and GI assisted with micro-injections and video recordings.

449

450   **Competing financial interests statement**

451   The authors declare no competing financial interests.

452

453   **Additional information**

454   **Supplementary Tables 1- 5**

455

456

457

458

459

460

461

462

463

464

465

466

467

468   **Figures**

469

470

471

472

473

474

475

476

477

478

479

480

481

482   **Figure 1 CRISPR-Cas9 targeting of *we* gene:** (A) A scheme of the *we* gene and the 3

483   sgRNAs targeted sites (denoted *we-g*1, *we-g2, we-g3*) (B) wildtype *we⁺/we⁺* (left) and

484   mutant *we/we* individual (right). (C) and (D) examples of somatic *we* clones in the eyes of

485   G0 individuals. (E) Sequences of mutant *we* alleles recovered from G0 individuals

486   targeted with *we-g*1 or *we-g*2. The CrispRVariants plots show sequence composition of

487   various alleles compared to reference (target sequence and PAM are boxed and position

488   of cut site is indicated with a black line). The label of individual allele denotes the

489   location (relative to the cut site) and the size of the deletion. Number of sequenced clones

490   per allele are shown in the yellow box. (F) Sequences of mutant *we* alleles in G0

491   individuals targeted with duplex *we-g*2 and *we-g*3 RNPs The CrispRVariants plot shows

492   the spectrum of induced deletions in G0 individuals. Black lines indicate the position of

493   the cute site in each target sequence (black boxes). > symbol signifies absence of mapped

494   sequence from a partial alignment.

495

496

497

498

499

Figure 2 CRISPR induced *we* non-complementing alleles transmitted to the G1 progeny. (A) homozygous wildtype *we*⁺ individual (left), homozygous mutant individual *we* (middle), G1 individual heterozygous for mutant *we* and CRISPr induced *we* mutation. (B) CrispRVariants plots of G1 mutant progeny of G0 targeted by *we-g*1 (3 sequences), targeted by *we-g*2 (1 sequence), *we-g3* (6 sequences) or *we*-g2+g3 (4 sequences).

509

510

511 **Figure 3 CRISP-Cas9 targeting of *Ccprd*. (A)** A scheme of the *Ccprd* gene and the

512 positions and sequences of two sgRNAs used for inducing NJEH lesions (B) Comparison

513 of the cuticular morphology of a non-injected control (wild type) and a sgRNA prd1

514 injected embryo (*prd1*-Cas9). The injected embryo is significantly shorter and displays a

515 twofold reduction in segment number reminiscent of the pair-rule phenotype described in

516 Drosophila. (C) After injection of *Ccprd*-g1, high variability in phenotypes was observed

517 ranging from wildtype appearance (2) to strong deformations and size reductions along

518 the main body axis. Similar phenotypes were observed also with *Ccprd*-g2 (D) A

519 CrispRVariants plot of *Ccprd* alleles found in larvae injected with RNP containing

520 *Ccprd-g1* sgRNA.

521

References

1   Liquido, N.J., Shinoda, L.A., Cunningham RT. Host plants of the Mediterranean fruit fly (Diptera, Tephritidae). An annotated world list. *Ann Entomol Soc Am.* **77:1–57.** (1991).

2   Dyck, V. A., Hendrics., J., & Robinson, A.S. . Sterile Insect Technique Principles and Practice in Area-Wide Integrated Pest Management. *Eds* **XIV, 787 p., ISBN: 1-4020-4050-4.** (2005).

3   Morrison, N.I., F. G., Koukidou M, Miller TA, Saccone G, Alphey LS, Beech CJ, Nagaraju J, Simmons GS, & Polito LC. Genetic improvements to the sterile insect technique for agricultural pests. *Asia Pacific Journal of Molecular Biology and Biotechnology* **18(2):275-295** (2010).

4   Loukeris, T. G., Livadaras, I., Arca, B., Zabalou, S. & Savakis, C. Gene-Transfer into the Medfly, *Ceratitis capitata*, with a *Drosophila hydei* Transposable Element. *Science* **270**, 2002-2005 (1995).

5   Zwiebel, L. J. *et al.* The *white* Gene of *Ceratitis capitata* - a Phenotypic Marker for Germline Transformation. *Science* **270**, 2005-2008 (1995).

6   Pane, A., Salvemini, M., Bovi, P. D., Polito, C. & Saccone, G. The *transformer* gene in *Ceratitis capitata* provides a genetic basis for selecting and remembering the sexual fate. *Development* **129**, 3715-3725 (2002).

7   Salvemini, M. *et al. Ceratitis capitata transformer-2* gene is required to establish and maintain the autoregulation of *Cctra*, the master gene for female sex determination. *Int J Dev Biol* **53**, 109-120 (2009).

8   Dafa'alla, T. H. *et al.* Transposon-free insertions for insect genetic engineering. *Nat Biotechnol* **24**, 820-821 (2006).

9   Gong, P. *et al.* A dominant lethal genetic system for autocidal control of the Mediterranean fruitfly. *Nat Biotechnol* **23**, 453-456 (2005).

548   10   Salvemini, M., Mauro, U., Velaeti, S., Polito, C. & Saccone, G. A new Minos
549   vector for eye-specific expression of white plus marker in *Ceratitis capitata* and
550   in distantly related dipteran species. *Insect Mol Biol* **15**, 341-349 (2006).

551   11   Schetelig, M. F., Caceres, C., Zacharopoulou, A., Franz, G. & Wimmer, E. A.
552   Conditional embryonic lethality to improve the sterile insect technique in
553   *Ceratitis capitata* (Diptera: Tephritidae). *Bmc Biol* **7**, **DOI:** 10.1186/1741-7007-
554   7-4 (2009).

555   12   Schetelig, M. F. *et al.* Site-specific recombination for the modification of
556   transgenic strains of the Mediterranean fruit fly *Ceratitis capitata*. *P Natl Acad*
557   *Sci USA* **106**, 18171-18176 (2009).

558   13   Fu, G. L. *et al.* Female-specific insect lethality engineered using alternative
559   splicing. *Nat Biotechnol* **25**, 353-357 (2007).

560   14   Ogaugwu, C. E., Schetelig, M. F. & Wimmer, E. A. Transgenic sexing system for
561   *Ceratitis capitata* (Diptera: Tephritidae) based on female-specific embryonic
562   lethality. *Insect Biochem Molec* Biol **43**, 1-8 (2013).

563   15   Saccone G. et al. (2007) New Sexing Strains for Mediterranean Fruit
564   Fly *Ceratitis capitata*: Transforming Females into Males. In: Vreysen M.J.B.,
565   Robinson A.S., Hendrichs J. (eds) Area-Wide Control of Insect Pests.
566   Springer, Dordrecht.

567   16   Scolari, F. *et al.* Fluorescent sperm marking to improve the fight against the pest
568   insect *Ceratitis capitata* (Wiedemann; Diptera : Tephritidae). *New Biotechnol* **25**,
569   76-84 (2008).

570   17   Kim, H. & Kim, J. S. A guide to genome engineering with programmable
571   nucleases. *Nat Rev Genet* **15**, 321-334 (2014).

572   18   Reid, W. & O'Brochta, D. A. Applications of genome editing in insects. *Curr*
573   *Opin Insect Sci* **13**, 43-54 (2016).

574   19   Gantz, V. M. & Bier, E. Genome editing. The mutagenic chain reaction: a method

575   for converting heterozygous to homozygous mutations. *Science* 348, 442–

576   444 (2015).

577   **20**   Gantz, V. M. *et al.* Highly efficient Cas9-mediated gene drive for population

578   modification of the malaria vector mosquito *Anopheles stephensi Proc. Natl*

579   *Acad. Sci. USA* 112, E6736–E6743 (2015).

580   21   Hammond, A. *et al.* A CRISPR-Cas9 gene drive system-targeting female

581   reproduction in the malaria mosquito vector *Anopheles gambiae*. *Nat Biotechnol*

582   **34**, 78-83 (2016).

583

584   22   Gratz, S. J. *et al.* Genome Engineering of *Drosophila* with the CRISPR RNA-

585   Guided Cas9 Nuclease. *Genetics* **194**, 1029-35 (2013).

586   23   Bassett, A. R., Tibbit, C., Ponting, C. P. & Liu, J. L. Highly Efficient Targeted

587   Mutagenesis of *Drosophila* with the CRISPR/Cas9 System. *Cell Rep* **4**, 220-228,

588   doi:10.1016/j.celrep.2013.06.020 (2013).

589   24   Yu, Z. S. *et al.* Highly Efficient Genome Modifications Mediated by

590   CRISPR/Cas9 in *Drosophila*. *Genetics* **195**, 289-291 (2013).

591   25   Kondo, S. & Ueda, R. Highly Improved Gene Targeting by Germline-Specific

592   Cas9 Expression in *Drosophila*. *Genetics* **195**, 715-21, (2013).

593   26   Ren, X. J. *et al.* Optimized gene editing technology for D*rosophila melanogaster*

594   using germ line-specific Cas9. *P Natl Acad Sci USA* **110**, 19012-19017, (2013).

595   27   Lee, J. S. *et al.* RNA-Guided Genome Editing in *Drosophila* with the Purified

596   Cas9 Protein. *G3-Genes Genom Genet* **4**, 1291-1295 (2014).

597   28   Basu, S. *et al.* Silencing of end-joining repair for efficient site-specific gene

598   insertion after TALEN/CRISPR mutagenesis in *Aedes aegypti*. *P Natl Acad Sci*

599   *USA* **112**, 4038-4043, (2015).

600 29 Kistler, K. E., Vosshall, L. B. & Matthews, B. J. Genome Engineering with
601   CRISPR-Cas9 in the Mosquito *Aedes aegypti*. *Cell Rep* **11**, 51-60,
602   doi:10.1016/j.celrep.2015.03.009 (2015).

603 30 Burger, A. *et al.* Maximizing mutagenesis with solubilized CRISPR-Cas9
604   ribonucleoprotein complexes. *Development* **143**, 2025-2037 (2016).

605 31 Zhang, X. H., Tee, L. Y., Wang, X. G., Huang, Q. S. & Yang, S. H. Off-target
606   Effects in CRISPR/Cas9-mediated Genome Engineering. *Mol Ther-Nucl Acids* **4**,
607   doi:ARTN e264 10.1038/mtna.2015.37 (2015).

608 32 Gomulski, L. M. *et al.* Genomic organization and characterization of the *white*
609   locus of the Mediterranean fruitfly, *Ceratitis capitata*. *Genetics* **157**, 1245-1255
610   (2001).

611 33 Zacharopoulou, A. Polytene Chromosome Maps in the Medfly *Ceratitis capitata*.
612   *Genome* **33**, 184-197 (1990).

613 34 Zacharopoulou, A. *et al.* The Genome of the Mediterranean Fruit-Fly *Ceratitis*
614   *capitata* - Localization of Molecular Markers by Insitu Hybridization to Salivary-
615   Gland Polytene Chromosomes. *Chromosoma* **101**, 448-455, doi:Doi
616   10.1007/Bf00582839 (1992).

617 35 Montague, T. G., Cruz, J. M., Gagnon, J. A., Church, G. M. & Valen, E.
618   CHOPCHOP: a CRISPR/Cas9 and TALEN web tool for genome editing. *Nucleic*
619   *Acids Res* **42**, W401-W407, doi:10.1093/nar/gku410 (2014).

620 36 Jinek, M. *et al.* Structures of Cas9 Endonucleases Reveal RNA-Mediated
621   Conformational Activation. *Science* **343**, 1215-+, doi:10.1126/science.1247997
622   (2014).

623 37 Nüsslein-Volhard, C., & Wieschaus, E. Mutations affecting segment number and
624   polarity in Drosophila. *Nature* **287** (1980).

625 38 Peel, A. D., Chipman, A. D. & Akam, M. Arthropod segmentation: Beyond the
626   Drosophila paradigm. *Nat Rev Genet* **6**, 905-916, doi:10.1038/nrg1724 (2005).

627   39   Bopp, D., Burri, M., Baumgartner, S., Frigerio, G. & Noll, M. Conservation of a
628   Large Protein Domain in the Segmentation Gene Paired and in Functionally
629   Related Genes of *Drosophila*. *Cell* **47**, 1033-1040, doi:Doi 10.1016/0092-
630   8674(86)90818-4 (1986).

631   40   Harvey-Samuel, T., Ant, T., Gong, H. F., Morrison, N. I. & Alphey, L.
632   Population-level effects of fitness costs associated with repressible female-lethal
633   transgene insertions in two pest insects. *Evol Appl* **7**, 597-606,
634   doi:10.1111/eva.12159 (2014).

635   41   Kanchiswamy, C. N., Malnoy, M., Velasco, R., Kim, J. S. & Viola, R. Non-GMO
636   genetically edited crop plants. *Trends Biotechnol* **33**, 489-491,
637   doi:10.1016/j.tibtech.2015.04.002 (2015).

638   42   Hwang, W. Y. *et al.* Efficient genome editing in zebrafish using a CRISPR-Cas
639   system. *Nat Biotechnol* **31**, 227-229, doi:10.1038/nbt.2501 (2013).

640   43   Gilles, A. F., Schinko, J. B. & Averof, M. Efficient CRISPR-mediated gene
641   targeting and transgene replacement in the beetle Tribolium castaneum.
642   *Development* **142**, 2832-+, doi:10.1242/dev.125054 (2015).

643   44   Canver, M. C. *et al.* Characterization of genomic deletion efficiency mediated by
644   clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 nuclease
645   system in mammalian cells. *The Journal of biological chemistry* **289**, 21312-
646   21324, doi:10.1074/jbc.M114.564625 (2014).

647   45   Papanicolaou, A. *et al.* The whole genome sequence of the Mediterranean fruit
648   fly, Ceratitis capitata (Wiedemann), reveals insights into the biology and adaptive
649   evolution of a highly invasive pest species. *Genome biology* **17**, 192,
650   doi:10.1186/s13059-016-1049-2 (2016).

651   46   Truppo E, Supuran CT, Sandomenico A, Vullo D, Innocenti A, Di Fiore A,
652   Alterio V, De Simone G, Monti SM. Carbonic anhydrase VII is S-
653   glutathionylated without loss of catalytic activity and affinity for sulfonamide
654   inhibitors. Bioorg Med Chem Lett. 2012 Feb 15;22(4):1560-4.

655   47   Dathan, N. A. *et al.* Biochemical characterization of the chloroplastic beta-

656   carbonic anhydrase from Flaveria bidentis (L.) "Kuntze". *Journal of enzyme*

657   *inhibition and medicinal chemistry* **29**, 500-504, (2014).

658   48   Holmes, D. S. & Bonner, J. Preparation, molecular weight, base composition, and

659   secondary structure of giant nuclear ribonucleic acid. *Biochemistry* **12**, 2330-

660   2338 (1973).

661   49   Lindsay H, et al. CrispRVariants charts the mutation spectrum of genome

662   engineering experiments. *Nature Biotechnology* **34,** 701–702 (2016).

663   50   Gabrieli and Scolari Delivery of Nucleic Acids through Embryo Microinjection

664   in the Worldwide Agricultural Pest Insect, *Ceratitis capitata*. *Journal of Visual*

665   *Experiments.* **116**, (2016).

666

667

668 **Supplementary Tables**

669

Cas9 µg/µl	Injected embryos	Larvae/ Embryos	Pupae/ Larvae	Adults/ Pupae
0	114	0.56(64)	0.84(54)	0.66(36)
0.9	150	0.59(88)	0.37(33)	0.82(27)
1.8	110	0.57(63)	0.49(31)	0.68(31)
3.6	134	0.51(69)	0.41(28)	0.71(20)

670

671

672 **Supplementary Table 1: Survival rates after injecting recombinant Cas9 protein**

673 **into embryos.**

674 Numbers represent the percentage of survivors (actual number in parentheses) for a given

675 specific developmental stage relative to number of individuals of the preceding stage.

676

677

678

Cas9 μg/μl	sgRNA 0.2 μg/μl	Injected embryos	Larvae/embryos	Pupae/larvae	Adults/ pupae	somatic mosaics
1.8	we-g1	240	0.56(134)	0.33(34)	0.18(6)	0.5(3)
1.8	we-g2	180	0.44(80)	0.36(29)	0,83(24)	0.04(1)
1.8	we-g3	200	0.46(92)	0.34(31)	0.64(20)	0
1.8	we-g1/ we-g2	240	0.43(104)	0.44(44)	0.95(42)	0.23(10)
1.8	we-g2/ we-g3	250	0.49(123)	0.53(58)	0.65(38)	0

679

680

681

682 **Supplementary Table 2: Survival rates and frequencies of individuals with somatic**

683 **mutant clones after injecting we-g RNPs**

684 Numbers represent the percentage of survivors (actual number in parentheses) for a given

685 specific developmental stage relative to number of individuals of the preceeding stage. 31

686 larvae which survived *we*-g1 injections (row 1), 5 larvae of *we*-g1/*we*-g2 (row 4) and 13

687 larvae of *we*-g2+ *we*-g3 injections (row 5) were sacrificed for molecular analysis.

688

689

Cas9 μg/μl	sgRNA 0.2 μg/μl	Injected embryos	Larvae/embryos	Pupae/larvae	Adults/ pupae	somatic mosaics

Line	Sex of founder	we/we^{CRISPR} flies	we/we^+ flies	Transmission rate
we-g1#1	M*	6	0	**1**
we-g1#2	M*	10	12	0.45
we-g2#3	F	0	55	0
we-g2#4	M	53	34	0.6
we-g2#5	M	113	2	**0.98**
we-g2#6	M	1	68	0.01
we-g2#7	M*	14	10	0.58

690

691

692 **Supplementary Table 3: Transmission of CRISPR-induced *we* mutations in the**

693 **germ line**

694 From 9 injected G0 flies 7 (RNPs *we*-g1 or *we*-g2; see first colown) produced progeny

695 with we phenotype when crossed to *we/we* mutant partners. 2 flies were sterile. The

696 highest transmission rates of CRISPr induced mutant we alleles (100% and 98%) are

697 shown in bold.

698

699

700

701

702

703

sgRNAs	G0 injected parents	we^{CRISPR} flies	we^+ flies	Total adult G1 flies	Mutants frequency
we-g3	8M x 12F	2	24	26	0.08
we-g2+ we-g3	18M x 20F	3	181	184	0.02

704

705

706 **Supplementary Table 4: Germline transmission of CRISPR-induced *we* mutations**

707

708 Progeny of two families of G0 injected adults are shown. All G0 injected individuals

709 from each of the 2 injection experiments shown in Table 4, were crossed and G1 scored

710 for we mutant flies.

711

712

713

714

Cas9 μg/μl	sgRNA μg/μl	embryos	larvae/embyos	pupae/larvae	adults/pupae
0	0	172	0.46(80)	0.74(59)	0.97(57)
1.8	0	110	0.57(63)	0.84(54)	0.68(31)
1.8	prd1 0.2	164	0.35(58)	0.17(10)	0.8(8)
1.8	prd1 0.2	244	0.24(58)	0.5(29)	0.96(28)

715

716

717

718

719 **Supplementary Table 5. Survival rates after injecting of Ccprd-g1 and Ccprd-g2**

720 **RNPs into syncytial embryos.**

721

722 Numbers represent the percentage of survivors (actual number in parentheses) for a given

723 specific developmental stage relative to number of individuals of the preceding stage.